W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

PARP1

PARP1

Overview

Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme encoded by the PARP1 gene and classified as a member of the PARP family of proteins. It functions as a central sensor and mediator of DNA damage repair, catalyzing the transfer of ADP-ribose units from nicotinamide adenine dinucleotide (NAD⁺) onto target proteins to form poly(ADP-ribose) (PAR) chains — a post-translational modification that recruits DNA repair machinery to sites of single- and double-strand breaks. Through its zinc-finger DNA-binding domains and catalytic domain, PARP1 is rapidly activated upon detecting DNA lesions, enabling base excision repair and other genomic maintenance pathways. Because PARP1 activity is tightly coupled to adenosine triphosphate consumption and cellular bioenergetics, its inhibition can precipitate profound metabolic and genotoxic stress in cancer cells.

PARP1's clinical relevance is most prominently established in the context of homologous recombination (HR)-deficient cancers. In tumor cells harboring mutations in BRCA1 or BRCA2, the simultaneous loss of HR and PARP1-mediated single-strand break repair creates a state of synthetic lethality, making such tumors exquisitely sensitive to PARP inhibitors (PARPis). This principle underpins the regulatory approval of several PARPis — including olaparib, niraparib, and rucaparib — for cancers including ovarian cancer, breast cancer, and endometrial cancer. Beyond synthetic lethality, PARP1 is implicated in regulating transcription, chromatin remodeling, inflammation, and apoptotic signaling, positioning it as a multifunctional target of broad therapeutic interest.

Focus of Latest Publications

PARP1 inhibition has emerged as a versatile therapeutic strategy across diverse cancer types, including breast, ovarian, endometrial, and cervical cancers, as well as glioblastoma. Recent studies demonstrate evolving approaches to enhance the therapeutic potential of PARP1-targeted agents, ranging from novel chemical modifications and delivery strategies to combination therapies and computational optimization of selectivity.

To overcome intrinsic limitations of PARP inhibitors—including poor bioavailability and inability to cross biological barriers—researchers have developed multiple conjugate and delivery strategies. These include radiolabeling of talazoparib with 211At for targeted alpha-particle radiotherapy, which demonstrated high tumor uptake and therapeutic efficacy in preclinical prostate and glioma models; conjugation of olaparib with a blood-brain barrier-penetrating heptamethine cyanine dye for glioblastoma treatment; attachment of olaparib to platinum-based compounds to enhance specificity and overcome cisplatin resistance in ovarian cancer; and propynylation of the natural product apigeninidin to improve cell membrane permeability and PARP1 targeting in cervical cancer cells.

Complementary therapeutic strategies pairing PARP1 inhibition with DNA-damaging or immunomodulatory agents continue to show promise. The DUO-E trial investigated olaparib combined with durvalumab and chemotherapy in advanced endometrial cancer, demonstrating reduced disease progression and improved survival across mismatch repair proficient and deficient populations. Novel hybrid molecules, such as olaparib-β-carboline compounds, synergistically combine PARP inhibition with DNA damage induction, showing potent anti-proliferative activity against BRCA-deficient triple-negative breast cancer cells and inducing G2/M cell cycle arrest and apoptosis.

Modern drug discovery pipelines employing computational and machine learning approaches are accelerating identification of novel PARP1 inhibitors. Fragment-based design coupled with artificial intelligence-predicted pharmacokinetics and anti-cancer potential identified candidate compounds against triple-negative breast cancer with enhanced stability and synthetic accessibility. Computational methods—including absolute binding free energy calculations and umbrella sampling—have elucidated selectivity determinants between PARP1 and PARP2, revealing how contact connectivity at the binding pocket controls inhibitor selectivity and informing future inhibitor optimization. Additionally, CRISPR-based approaches have identified PARP1 as a synthetic lethal target in BRCA1-deficient tumors, extending the therapeutic rationale for PARP1-targeted precision oncology.

Key Publications

  • NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42257398)
  • Apr In Vitro Evaluation of PARP1 Inhibitor Olaparib-Cyanine Dye Conjugate for the Treatment of Glioblastoma. (ChemMedChem, 2026, PMID 42035252): "This study presents the proof of concept in vitro cellular activity of PARP1 (Poly(ADP-ribose) polymerase 1) enzyme inhibitor olaparib conjugated with a known BBB-crossing heptamethine cyanine dye."
  • May Comparative Assessment of Free Energy Computational Methods for Revealing the Interactions Driving PARP1 Selective Inhibition. (Journal of chemical information and modeling, 2026, PMID 41999312): "...recapitulate PARP1 versus PARP2 selectivity for eight clinically relevant PARP enzyme inhibitors..."
  • May Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair. (Inorganic chemistry, 2026, PMID 41996568): "a new PARP1-specific Pt(II)-based TDC for the treatment of ovarian cancer was reported."
  • Apr Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer. (Future oncology (London, England), 2026, PMID 41943281): "Olaparib inhibits a protein called PARP (poly [ADP-ribose] polymerase), thereby stopping cancer cells from being able to repair their DNA."
  • Apr CRISPR-mediated cancer therapies: Approaches to direct tumor targeting. (Critical reviews in oncology/hematology, 2026, PMID 41833894): "CRISPR screening has identified synthetic lethal interactions, such as PARP1 dependency in BRCA1-/- tumors."
  • Apr Fragment-based drug design coupled with AI/ML prediction enables identification of novel PARP-1 inhibitors against triple-negative breast cancer. (Journal of molecular graphics & modelling, 2026, PMID 41724073): "The approval of PARP-1 inhibitors against Triple-negative Breast Cancer (TNBC) paves the way for drug discovery endeavours in this arena."
  • May Site-specific propynylation modification of apigeninidin enhances anti-cervical cancer activity by targeting PARP-1. (Bioorganic chemistry, 2026, PMID 41653678): "In addition, chemical proteomics enrichment analyses indicated that APN-A shows its antitumor effects primarily by targeting and inhibiting processes such as DNA replication and protein transcription-translation in cancer cells via targeting proteins such as PARP-1, EIF3J, and TCEA1."
  • May Discovery of novel olaparib-β-carboline hybrids for treating BRCA-deficient triple negative breast cancer. (Bioorganic & medicinal chemistry, 2026, PMID 41643574): "Moreover, compound 6 potently inhibited PARP-1 and PARP-2, with IC50 values of 1.6±0.7 and 0.9±0.2 nM, respectively."
Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.